Cargando…
Extended anticoagulation for unprovoked venous thromboembolism
After completing anticoagulation therapy for acute venous thromboembolism (VTE), patients with unprovoked VTE are at increased risk of recurrent thrombotic events. Recent studies suggest a risk of nearly 10% in the first year after stopping anticoagulants and 30% at 8 years. Therefore, it is importa...
Autores principales: | Castellucci, Lana A., de Wit, Kerstin, Garcia, David, Ortel, Thomas L., Le Gal, Grégoire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046599/ https://www.ncbi.nlm.nih.gov/pubmed/30046758 http://dx.doi.org/10.1002/rth2.12121 |
Ejemplares similares
-
Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022) -
Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?
por: Moodley, Otto, et al.
Publicado: (2015) -
Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol
por: Khan, Faizan, et al.
Publicado: (2019) -
Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism
por: Khan, Faizan, et al.
Publicado: (2023) -
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)